IDSA guideline update adds a new recommendation on baricitinib vs tocilizumab for hospitalised adults with severe or critical COVID-19 when one or the other is to be given, based on a systematic review and GRADE; combinations are not addressed.
Guideline
Nadig et al. 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Baricitinib vs. Tocilizumab